Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. M. Gauvreau, L. P. Boulet, R. Leigh, D. W. Cockcroft, B. E. Davis, I. Mayers, J. M. FitzGerald, B. Dahlen, R. M. Watson, J. Milot, V. Swystun, L. Hui, A. S. Lantz, M. Bowen, J. Arm, S. Maahs, K. Meiser, P. Lowe, A. Skerjanec, C. Carlsten, K. Strandberg, K. J. Killian, M. Laviolette, A. Drollmann, P. M. O'Byrne (Hamilton, Québec, Calgary, Saskatoon, Edmonton, Vancouver, Canada; Stockholm, Sweden; Basel, Switzerland; East Hanover, United States Of America). LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response. Eur Respir J 2014; 44: Suppl. 58, 2910

Member's Comments

No comment yet.

Related content which might interest you: QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 A PKPD mathematical model to determine efficacy of multiple doses of QGE031 (ligelizumab) vs. omalizumab and placebo in inhibiting skin responses in atopic asthmatics Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 The impact of sublingual allergen-specific therapy on asthma control and quality of life Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Tolerability and adherence to sublingual immunotherapy with mite vaccines with different schedule in asthmatic children Source: International Congress 2014 – More paediatric asthma Year: 2014 QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Serum IL-10 and IL-17 are not related to the efficacy of allergen specific immunotherapy in asthma Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme Source: International Congress 2014 – Latest insights in airway diseases Year: 2014